bioRxivBiochemistryPreprint
Orthogonal resistance mechanisms of classical- and induced-proximity inhibitors
Manuel L. MerziD, Karishma KailassiD, Rajaiah PerguiD, Kien TraniD, Kritika GuptaiD, Zachary C. SeveranceiD, Sameek SinghiD, Vedagopuram SreekanthiD, Benjamin K. Law, Gideon Rosenblatt, Rohil DhaliwaliD, Amit ChoudharyiD
Abstract
Resistance development is an inevitable failure mode of many drugs, pointing to the need to develop agents with orthogonal resistance mechanisms. Induced-proximity modalities, an emergent class of therapeutics, operate by forming a ternary complex with the protein-of-interest (POI) and effectors, unlike classical inhibitors that form binary complexes with the POI. Using KRAS as a model system, we employed base editor tiling mutagenesis screening to show that induced-proximity inhibitors exhibit orthogonal resistance mechanisms to classical inhibitors despite overlapping binding sites, offering an opportunity to circumvent resistance mechanisms of classical inhibitors. These findings highlight the use of base editor mutagenesis screens to prioritize inhibitors with orthogonal resistance mechanisms and the potential of induced-proximity inhibitors to overcome the drug resistance of classical inhibitors.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic mechanisms of resistance to targeted KRAS inhibition
Bianca Jay Diaz, M.S. Kops, … Lukas E. Dow·bioRxiv·Aug 4, 2025
- Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition
Katherine Parker, Samar Ghorbanpoor, … Aaron N. Hata·bioRxiv·Apr 30, 2026
- KRAS G12D can be targeted by potent salt-bridge forming inhibitors
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
B. Daley, H. M. Vieira, … R. L. Kortum·bioRxiv·Dec 6, 2022
- Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector binding
M. J. McCarthy, C. V. Pagba, … A. A. Gorfe·bioRxiv·Oct 11, 2018
- Profiling of the drug resistance of thousands of Src tyrosine kinase mutants uncovers a regulatory network that couples autoinhibition to catalytic domain dynamics
S. Chakraborty, E. Ahler, … D. J. Maly·bioRxiv·Dec 5, 2021